CAR T-Cell therapy trial for lymphoma pulled before it started
NCT ID NCT06313996
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to compare a CAR T-cell therapy called Liso-cel against standard treatments for adults with follicular lymphoma that had come back or stopped responding to previous therapy. The trial was a large Phase 3 study planned at multiple hospitals worldwide, but it was withdrawn before any patients were enrolled. No results or safety data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lisocabtagene maraleucel (Liso-cel, also known as BREYANZI)
- What this could lead to
- If successful, this could offer a more effective treatment option for people with follicular lymphoma that has returned or not responded to prior therapy.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no results are available. CAR T-cell therapies can cause serious side effects like cytokine release syndrome and neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.